Small Molecule Drug Discovery Market Size, Demand, Report to 2033

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Small Molecule Drug Discovery Market Size Analysis

Global Small Molecule Drug Discovery Market Introduction
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Oncology
  1. By Value
3. Central Nervous System
  1. By Value
4. Cardiovascular
  1. By Value
5. Respiratory
  1. By Value
6. Metabolic Disorders
  1. By Value
7. Gastrointestinal
  1. By Value
8. Other Therapeutic Areas
  1. By Value
By Process/Phase
1. Introduction
  1. Process/Phase By Value
2. Target ID/Validation
  1. By Value
3. Hit Generation and Selection
  1. By Value
4. Lead Identification
  1. By Value
5. Lead Optimization
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Pharmaceutical companies
  1. By Value
3. Biotechnology companies
  1. By Value
4. Contract research organizations (CROs)
  1. By Value
5. Others
  1. By Value

North America Market Analysis

Introduction
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Oncology
  1. By Value
3. Central Nervous System
  1. By Value
4. Cardiovascular
  1. By Value
5. Respiratory
  1. By Value
6. Metabolic Disorders
  1. By Value
7. Gastrointestinal
  1. By Value
8. Other Therapeutic Areas
  1. By Value
By Process/Phase
1. Introduction
  1. Process/Phase By Value
2. Target ID/Validation
  1. By Value
3. Hit Generation and Selection
  1. By Value
4. Lead Identification
  1. By Value
5. Lead Optimization
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Pharmaceutical companies
  1. By Value
3. Biotechnology companies
  1. By Value
4. Contract research organizations (CROs)
  1. By Value
5. Others
  1. By Value
U.S.
1. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Oncology
    1. By Value
  3. Central Nervous System
    1. By Value
  4. Cardiovascular
    1. By Value
  5. Respiratory
    1. By Value
  6. Metabolic Disorders
    1. By Value
  7. Gastrointestinal
    1. By Value
  8. Other Therapeutic Areas
    1. By Value
2. By Process/Phase
  1. Introduction
    1. Process/Phase By Value
  2. Target ID/Validation
    1. By Value
  3. Hit Generation and Selection
    1. By Value
  4. Lead Identification
    1. By Value
  5. Lead Optimization
    1. By Value
3. By End User
  1. Introduction
    1. End User By Value
  2. Pharmaceutical companies
    1. By Value
  3. Biotechnology companies
    1. By Value
  4. Contract research organizations (CROs)
    1. By Value
  5. Others
    1. By Value
Canada

Europe Market Analysis

Introduction
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Oncology
  1. By Value
3. Central Nervous System
  1. By Value
4. Cardiovascular
  1. By Value
5. Respiratory
  1. By Value
6. Metabolic Disorders
  1. By Value
7. Gastrointestinal
  1. By Value
8. Other Therapeutic Areas
  1. By Value
By Process/Phase
1. Introduction
  1. Process/Phase By Value
2. Target ID/Validation
  1. By Value
3. Hit Generation and Selection
  1. By Value
4. Lead Identification
  1. By Value
5. Lead Optimization
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Pharmaceutical companies
  1. By Value
3. Biotechnology companies
  1. By Value
4. Contract research organizations (CROs)
  1. By Value
5. Others
  1. By Value
U.K.
1. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Oncology
    1. By Value
  3. Central Nervous System
    1. By Value
  4. Cardiovascular
    1. By Value
  5. Respiratory
    1. By Value
  6. Metabolic Disorders
    1. By Value
  7. Gastrointestinal
    1. By Value
  8. Other Therapeutic Areas
    1. By Value
2. By Process/Phase
  1. Introduction
    1. Process/Phase By Value
  2. Target ID/Validation
    1. By Value
  3. Hit Generation and Selection
    1. By Value
  4. Lead Identification
    1. By Value
  5. Lead Optimization
    1. By Value
3. By End User
  1. Introduction
    1. End User By Value
  2. Pharmaceutical companies
    1. By Value
  3. Biotechnology companies
    1. By Value
  4. Contract research organizations (CROs)
    1. By Value
  5. Others
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Oncology
  1. By Value
3. Central Nervous System
  1. By Value
4. Cardiovascular
  1. By Value
5. Respiratory
  1. By Value
6. Metabolic Disorders
  1. By Value
7. Gastrointestinal
  1. By Value
8. Other Therapeutic Areas
  1. By Value
By Process/Phase
1. Introduction
  1. Process/Phase By Value
2. Target ID/Validation
  1. By Value
3. Hit Generation and Selection
  1. By Value
4. Lead Identification
  1. By Value
5. Lead Optimization
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Pharmaceutical companies
  1. By Value
3. Biotechnology companies
  1. By Value
4. Contract research organizations (CROs)
  1. By Value
5. Others
  1. By Value
China
1. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Oncology
    1. By Value
  3. Central Nervous System
    1. By Value
  4. Cardiovascular
    1. By Value
  5. Respiratory
    1. By Value
  6. Metabolic Disorders
    1. By Value
  7. Gastrointestinal
    1. By Value
  8. Other Therapeutic Areas
    1. By Value
2. By Process/Phase
  1. Introduction
    1. Process/Phase By Value
  2. Target ID/Validation
    1. By Value
  3. Hit Generation and Selection
    1. By Value
  4. Lead Identification
    1. By Value
  5. Lead Optimization
    1. By Value
3. By End User
  1. Introduction
    1. End User By Value
  2. Pharmaceutical companies
    1. By Value
  3. Biotechnology companies
    1. By Value
  4. Contract research organizations (CROs)
    1. By Value
  5. Others
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Oncology
  1. By Value
3. Central Nervous System
  1. By Value
4. Cardiovascular
  1. By Value
5. Respiratory
  1. By Value
6. Metabolic Disorders
  1. By Value
7. Gastrointestinal
  1. By Value
8. Other Therapeutic Areas
  1. By Value
By Process/Phase
1. Introduction
  1. Process/Phase By Value
2. Target ID/Validation
  1. By Value
3. Hit Generation and Selection
  1. By Value
4. Lead Identification
  1. By Value
5. Lead Optimization
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Pharmaceutical companies
  1. By Value
3. Biotechnology companies
  1. By Value
4. Contract research organizations (CROs)
  1. By Value
5. Others
  1. By Value
UAE
1. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Oncology
    1. By Value
  3. Central Nervous System
    1. By Value
  4. Cardiovascular
    1. By Value
  5. Respiratory
    1. By Value
  6. Metabolic Disorders
    1. By Value
  7. Gastrointestinal
    1. By Value
  8. Other Therapeutic Areas
    1. By Value
2. By Process/Phase
  1. Introduction
    1. Process/Phase By Value
  2. Target ID/Validation
    1. By Value
  3. Hit Generation and Selection
    1. By Value
  4. Lead Identification
    1. By Value
  5. Lead Optimization
    1. By Value
3. By End User
  1. Introduction
    1. End User By Value
  2. Pharmaceutical companies
    1. By Value
  3. Biotechnology companies
    1. By Value
  4. Contract research organizations (CROs)
    1. By Value
  5. Others
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Oncology
  1. By Value
3. Central Nervous System
  1. By Value
4. Cardiovascular
  1. By Value
5. Respiratory
  1. By Value
6. Metabolic Disorders
  1. By Value
7. Gastrointestinal
  1. By Value
8. Other Therapeutic Areas
  1. By Value
By Process/Phase
1. Introduction
  1. Process/Phase By Value
2. Target ID/Validation
  1. By Value
3. Hit Generation and Selection
  1. By Value
4. Lead Identification
  1. By Value
5. Lead Optimization
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Pharmaceutical companies
  1. By Value
3. Biotechnology companies
  1. By Value
4. Contract research organizations (CROs)
  1. By Value
5. Others
  1. By Value
Brazil
1. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Oncology
    1. By Value
  3. Central Nervous System
    1. By Value
  4. Cardiovascular
    1. By Value
  5. Respiratory
    1. By Value
  6. Metabolic Disorders
    1. By Value
  7. Gastrointestinal
    1. By Value
  8. Other Therapeutic Areas
    1. By Value
2. By Process/Phase
  1. Introduction
    1. Process/Phase By Value
  2. Target ID/Validation
    1. By Value
  3. Hit Generation and Selection
    1. By Value
  4. Lead Identification
    1. By Value
  5. Lead Optimization
    1. By Value
3. By End User
  1. Introduction
    1. End User By Value
  2. Pharmaceutical companies
    1. By Value
  3. Biotechnology companies
    1. By Value
  4. Contract research organizations (CROs)
    1. By Value
  5. Others
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Small Molecule Drug Discovery Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

AstraZeneca
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
4SC AG
Immunocure Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Gilead Sciences Inc.
GlaxoSmithKline PLC
Merck KGaA
Hoffmann-La Roche Ltd
Accent Therapeutics
Anima Biotech Inc.
Takeda Pharmaceutical Company Limited.
Charles River Laboratories
Eurofins Discovery
Astellas Pharma Inc.

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment